An observational study in Aortic Valve Stenosis and Transcatheter Aortic Valve Replacement, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Aortic Valve Stenosis with a site in Canada — 23 open to participants now, 36 under way, 1 of them phase 3. Aortic Valve Stenosis · Canada.
Among the 87 studies in Aortic Valve Stenosis with a site in Canada, this one is the 21st largest by planned enrollment of the 27 observational ones that give a count, is one of 3 that started in 2024, is one of 27 observational ones, reaches primary completion later than 23 of the 35 other live ones, and was the 81st registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →23 of the 87 studies in Aortic Valve Stenosis with a site in Canada are open now. Recruiting first, the newest first:
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in Canada
Ages 18+
Kardigan, Inc. · Sites in Canada, United States
Ages 50+
World Health Research Inc. · Sites in Canada, Australia, Colombia and 5 more countries
Novartis Pharmaceuticals · Sites in Canada, United States, Austria and 12 more countries
Ages 50–80
Edwards Lifesciences · Sites in Canada, United States
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 7 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 300 across the 60 interventional studies, 320 across the 27 observational. Of the 44 that completed or were terminated, 18 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 87 have an industry lead sponsor. The 10 most frequent:
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval is the lead sponsor of 15 studies on the registry; 9 are open to participants now.
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval has 5 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Aortic Valve Stenosis with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06991517World Health Research Inc.A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm | 2026-12 |
| NCT06816888Ottawa Heart Institute Research CorporationImpact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology | 2026-12-01 |
| NCT04464655McGill University Health Centre/Research Institute of the McGill University Health CentreA 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease | 2026-12-19 |
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 8 to your calendar (.ics) → With an account.
Among the 87 studies in Aortic Valve Stenosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The issue of valve durability has become one of the most important aspects in the TAVR field in recent years since transcatheter aortic valve replacement has been progressively applied to younger patients with a low co-morbidity burden. The SAPIEN 3 Ultra RESILIA valve represents the last generation of the SAPIEN valve system and includes several important iterations (newer leaflet calcium-blocking technology targeting calcium-attracting free aldehydes, dry tissue storage, newer skirt textile design) that should translate into a favorable impact on valve durability at mid- to long- term follow-up
Prospective observational registry including patients with severe aortic stenosis undergoing TAVR with the SAPIEN 3 Ultra RESILIA valve. All patients who will survive the procedure will undergo a clinical and echocardiographic follow-up at 1-3 months (± 15 days), at 1-year (±30 days), 3-5 year (±30 days), 6-8 year (±30 days) and 9-10 year (±30 days) after valve implantation. Transthoracic echocardiography (TTE) exams (baseline, 1-3-month, 1 year, 3-5 years, 6-8 years, and 9-10 years post-procedure) will be evaluated in a Centralized Echocardiographic Core Lab at the Quebec Heart and Lung Institute. The measurements obtained in the Core Lab regarding transvalvular gradient, EOA, PPM and PVL at 1-3 months will determine the primary outcome of the study.
Population Patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 Ultra RESILIA valve.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
VARC-3- defined technical success defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.
Transvalvular gradient
Residual (peak and mean) transvalvular gradient
Time frame: 1-3 months
Effective orifice area (EOA)
EOA evaluated by echocardiography imaging
Time frame: 1-3 months
Prosthesis-patient mismatch
Moderate or severe prothesis-patient mismatch (defines as an index aortic valve area 0.85-0.66 cm2/m2 (moderate), ≤0.65 cm2/m2 (severe) for patient with BMI ˂30km/m2 and 0.70-0.56 cm2/m2 (moderate), ≤0.55 cm2/m2 (severe) for patient with BMI ≥30km/m2 and/or moderate-severe aortic regurgitation (AR) (VARC-3 definition).
Time frame: 1-3 months
Paravalvular leaks
Paravalvular leaks evaluated by echocardiography imaging
Time frame: 1-3 months
Transvalvular gradient
Residual (maximal and mean) transvalvular gradient
Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.
Effective orifice area (EOA)
EOA evaluated by echocardiography imaging
Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.
Bioprosthetic valve dysfunction
Bioprosthetic valve dysfunction evaluated by VARC3 criteria
Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.
Paravalvular leaks
Paravalvular leaks evaluated by echocardiography imaging
Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.
Bioprosthetic valve dysfunction
Incidence rate (per 100 patient-years) of bioprosthetic valve dysfunction (stage 2 or 3)
Time frame: yearly
Bioprosthetic valve failure
Incidence rate (per 100 patient-years) of bioprosthetic valve failure
Time frame: yearly
Bioprosthetic valve failure
Bioprosthetic valve failure evaluated by VARC3 criteria
Time frame: 1-, 3-5-, 6-8-, and 9-10-year follow-up.
Clinical events
Individual: mortality, stroke, bleeding type 2-4, cardiac rehospitalization, heart failure rehospitalization
Time frame: 1month and yearly up to 10-year
Valve thrombosis
Number of patients with valve thrombosis
Time frame: 1-3 months and yearly up to 10-year
Valve endocarditis
Number of patients with valve endocarditis
Time frame: 1-3 months and yearly up to 10-year
Started May 2024 (actual). Primary completion is estimated for Oct 2027, 40 months after the start.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 40 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Oct 2027, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval